metricas

Actas Urológicas Españolas

Sugerencias
Actas Urológicas Españolas Consenso multidisciplinar sobre idoneidad farmacológica en cáncer de próstata...
Información de la revista
Vol. 47. Núm. 2.
Páginas 65-126 (Marzo 2023)
Cita
Cita
Compartir
Descargar PDF
Más opciones de artículo
Visitas
2184
Vol. 47. Núm. 2.
Páginas 65-126 (Marzo 2023)
ARTÍCULO ESPECIAL

Consenso multidisciplinar sobre idoneidad farmacológica en cáncer de próstata hormono-sensible metastásico

A multidisciplinary consensus statement on the optimal pharmacological treatment for metastatic hormone-sensitive prostate cancer
Visitas
2184
A. Borque-Fernandoa,
Autor para correspondencia
dr.borque@gmail.com

Autor para correspondencia.
, M.A. Calleja-Hernándezb, J.M. Cózar-Olmoc, A. Gómez-Iturriagad, D.A. Pérez-Fentese, J. Puente-Vázquezf, M. Rodrigo-Aliagag, M. Undah, J.L. Álvarez-Ossorioi
a Servicio de Urología, Hospital Universitario Miguel Servet, IIS-Aragón, Zaragoza, España
b Servicio de Farmacia, Hospital Universitario Virgen Macarena, Sevilla, España
c Servicio de Urología, Hospital Universitario Virgen de las Nieves, Granada, España
d Servicio de Oncología Radioterápica, Hospital Universitario Cruces, Biocruces Bizkaia Health Research Insitute, Barakaldo, Bizkaia, España
e Servicio de Urología, Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, A Coruña, España
f Servicio de Oncología Médica, Hospital Clínico Universitario San Carlos, Madrid, España
g Servicio de Urología, Hospital General Universitario de Castellón, Castellón, España
h Servicio de Urología, Hospital Universitario Basurto, Bilbao, España
i Servicio de Urología, Hospital Universitario Puerta del Mar, Cádiz, España
Ver más
Contenido relacionado
R. García-Fumero, M. Piñero-González
Este artículo ha recibido
Información del artículo
Resumen
Texto completo
Bibliografía
Descargar PDF
Estadísticas
Resumen

La terapia de privación androgénica (TPA) es el pilar del tratamiento del cáncer de próstata hormono-sensible metastásico (CPHSm). La adición de docetaxel o de nuevas terapias hormonales (abiraterona, apalutamida o enzalutamida) mejora la supervivencia global (SG) y es en la actualidad el estándar de tratamiento. Sin embargo, la decisión sobre el régimen específico que acompañe a la TPA debe ser discutida con el paciente teniendo en cuenta factores como las posibles toxicidades asociadas, la duración del tratamiento, las comorbilidades o sus preferencias, pues no hay evidencia suficiente para recomendar un régimen sobre otro en la mayoría de los casos. En este trabajo se resume la evidencia sobre el manejo del CPHSm y se aportan recomendaciones consensuadas sobre el tratamiento óptimo para añadir a la TPA en pacientes con CPHSm con especial atención al perfil clínico del paciente.

Palabras clave:
Cáncer de próstata
Metástasis de la neoplasia
Seguridad del paciente
Toma de decisiones clínicas
Prioridad del paciente
Antagonistas de andrógenos
Docetaxel
Abstract

Androgen deprivation therapy (ADT) is the mainstay treatment for metastatic hormone-sensitive prostate cancer (mHSPC). The addition of docetaxel or new hormone therapies (abiraterone, apalutamide, or enzalutamide) improves overall survival and is currently the standard of care. However, the decision on the specific regimen to accompany ADT should be discussed with the patient, considering factors such as possible associated toxicities, duration of treatment, comorbidities, patient preferences, as there is no sufficient evidence to recommend one regimen over the other in most cases. This paper summarizes the evidence on the management of mHSPC and provides consensus recommendations on the optimal treatment in combination with ADT in mHSPC patients, with special attention to the patient's clinical profile.

Keywords:
Prostate cancer
Neoplasm metastasis
Patient safety
Clinical decision-making
Patient preference
Androgen antagonists
Docetaxel

Artículo

Opciones para acceder a los textos completos de la publicación Actas Urológicas Españolas
Suscriptor
Suscriptor de la revista

Si ya tiene sus datos de acceso, clique aquí.

Si olvidó su clave de acceso puede recuperarla clicando aquí y seleccionando la opción "He olvidado mi contraseña".
Comprar
Comprar acceso al artículo

Comprando el artículo el PDF del mismo podrá ser descargado

Comprar ahora
Contactar
Teléfono para suscripciones e incidencias
De lunes a viernes de 9h a 18h (GMT+1) excepto los meses de julio y agosto que será de 9 a 15h
Llamadas desde España
932 415 960
Llamadas desde fuera de España
+34 932 415 960
E-mail
Bibliografía
[1]
Asociación Española de Urología [Internet]. [consultado 30 Sep. 2022]. Disponible en: https://www.aeu.es/libros.aspx
[2]
A. González del Alba, M.J. Méndez-Vidal, S. Vazquez, E. Castro, M.A. Climent, E. Gallardo, et al.
SEOM clinical guidelines for the treatment of advanced prostate cancer (2020).
Clin Transl Oncol., 23 (2021), pp. 969-979
[3]
C. Parker, E. Castro, K. Fizazi, A. Heidenreich, P. Ost, G. Procopio, et al.
Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Ann Oncol., 31 (2020), pp. 1119-1134
[4]
K.S. Virgo, R.B. Rumble, R. de Wit, D.S. Mendelson, T.J. Smith, M.E. Taplin, et al.
Initial Management of Noncastrate Advanced Recurrent, or Metastatic Prostate Cancer: ASCO Guideline Update.
J Clin Oncol., 39 (2021), pp. 1274-1305
[5]
EAU Guidelines on Prostate Cancer - Uroweb [Internet]. Uroweb - Eur. Assoc. Urol. [consultado 22 Jun. 2022]. Disponible en: https://uroweb.org/guidelines/prostate-cancer
[6]
W.T. Lowrance, R.H. Breau, R. Chou, B.F. Chapin, T. Crispino, R. Dreicer, et al.
Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline PART I.
[7]
AEMPS. Darolutamida. Ficha técnica [Internet]. [consultado 22 Jun. 2022]. Disponible en: https://cima.aemps.es/cima/publico/lista.html
[8]
M.R. Smith, M. Hussain, F. Saad, K. Fizazi, C.N. Sternberg, E.D. Crawford, et al.
Darolutamide and Survival in Metastatic Hormone-Sensitive Prostate Cancer.
N Engl J Med., 386 (2022), pp. 1132-1142
[9]
S. Feyerabend, F. Saad, T. Li, T. Ito, J. Diels, S. Van Sanden, et al.
Survival benefit, disease progression and quality-of-life outcomes of abiraterone acetate plus prednisone versus docetaxel in metastatic hormone-sensitive prostate cancer: A network meta-analysis.
Eur J Cancer., 1990 (2018), pp. 78-87
[10]
M. Marchioni, M. Di Nicola, G. Primiceri, G. Novara, P. Castellan, A.K. Paul, et al.
New Antiandrogen Compounds Compared to Docetaxel for Metastatic Hormone Sensitive Prostate Cancer: Results from a Network Meta-Analysis.
J Urol., 203 (2020), pp. 751-759
[11]
G. Napoli, S. Arcangeli, B. Fionda, F. Munoz, U. Tebano, E. Durante, et al.
A Systematic Review and a Meta-analysis of Randomized Controlled Trials’ Control Groups in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC).
Curr Oncol Rep., 24 (2022), pp. 1633-1644
[12]
N.J. Sathianathen, S. Koschel, I.A. Thangasamy, J. Teh, O. Alghazo, G. Butcher, et al.
Indirect Comparisons of Efficacy between Combination Approaches in Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review and Network Meta-analysis.
Eur Urol., 77 (2020), pp. 365-372
[13]
C.J.D. Wallis, Z. Klaassen, B. Bhindi, H. Goldberg, T. Chandrasekar, A.M. Farrell, et al.
Comparison of Abiraterone Acetate and Docetaxel with Androgen Deprivation Therapy in High-risk and Metastatic Hormone-naïve Prostate Cancer: A Systematic Review and Network Meta-analysis.
Eur Urol., 73 (2018), pp. 834-844
[14]
National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Prostate Cancer. Version 1.2023 — September 16, 2022. [Internet]. NCCN [consultado 19 Oct. 2022]. Disponible en: https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf
[15]
AEMPS. Docetaxel. Ficha técnica. [Internet]. [consultado 22 Jun. 2022]. Disponible en: https://cima.aemps.es/cima/publico/lista.html
[16]
C. Baston, A. Preda, S.S. Guler-Margaritis, I. Sinescu, C. Gingu.
Systemic treatment options for metastatic hormone-sensitive prostate cancer: making sense of the data.
Curr Opin Urol., 30 (2020), pp. 576-583
[17]
C.E. Kyriakopoulos, Y.H. Chen, M.A. Carducci, G. Liu, D.F. Jarrard, N.M. Hahn, et al.
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial.
J Clin Oncol., 36 (2018), pp. 1080-1087
[18]
C.J. Sweeney, Y.H. Chen, M. Carducci, G. Liu, D.F. Jarrard, M. Eisenberger, et al.
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer.
N Engl J Med., 373 (2015), pp. 737-746
[19]
N.W. Clarke, A. Ali, F.C. Ingleby, A. Hoyle, C.L. Amos, G. Attard, et al.
Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial.
Ann Oncol., 30 (2019), pp. 1992-2003
[20]
N.D. James, M.R. Sydes, N.W. Clarke, M.D. Mason, D.P. Dearnaley, M.R. Spears, et al.
Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial.
Lancet Lond Engl., 387 (2016), pp. 1163-1177
[21]
G. Gravis, K. Fizazi, F. Joly, S. Oudard, F. Priou, B. Esterni, et al.
Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial.
Lancet Oncol., 14 (2013), pp. 149-158
[22]
G. Gravis, J.M. Boher, F. Joly, M. Soulié, L. Albiges, F. Priou, et al.
Androgen Deprivation Therapy (ADT) Plus Docetaxel Versus ADT Alone in Metastatic Non castrate Prostate Cancer: Impact of Metastatic Burden and Long-term Survival Analysis of the Randomized Phase 3 GETUG-AFU15 Trial.
Eur Urol., 70 (2016), pp. 256-262
[23]
AEMPS. Abiraterona. Ficha técnica. [Internet]. [consultado 22 Jun. 2022]. Disponible en: https://cima.aemps.es/cima/publico/lista.html
[24]
K. Fizazi, N. Tran, L. Fein, N. Matsubara, A. Rodriguez-Antolin, B.Y. Alekseev, et al.
Abiraterone plus Prednisone in Metastatic Castration-Sensitive Prostate Cancer.
N Engl J Med., 377 (2017), pp. 352-360
[25]
K. Fizazi, N. Tran, L. Fein, N. Matsubara, A. Rodriguez-Antolin, B.Y. Alekseev, et al.
Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial.
Lancet Oncol., 20 (2019), pp. 686-700
[26]
N.D. James, J.S. de Bono, M.R. Spears, N.W. Clarke, M.D. Mason, D.P. Dearnaley, et al.
Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy.
N Engl J Med., 377 (2017), pp. 338-351
[27]
N.D. James, N.W. Clarke, A. Cook, A. Ali, A.P. Hoyle, G. Attard, et al.
Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5-year follow-up results from the STAMPEDE randomised trial (NCT00268476).
Int J Cancer., 151 (2022), pp. 422-434
[28]
AEMPS. Apalutamida. Ficha técnica. [Internet]. [consultado 22 Jun. 2022]. Disponible en: https://cima.aemps.es/cima/publico/lista.html
[29]
K.N. Chi, N. Agarwal, A. Bjartell, B.H. Chung, A.J. Pereira de Santana Gomes, R. Given, et al.
Apalutamide for Metastatic Castration-Sensitive Prostate Cancer.
N Engl J Med., 381 (2019), pp. 13-24
[30]
K.N. Chi, S. Chowdhury, A. Bjartell, B.H. Chung, A.J. Pereira de Santana Gomes, R. Given, et al.
Apalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer: Final Survival Analysis of the Randomized, Double-Blind Phase III TITAN Study.
J Clin Oncol., 39 (2021), pp. 2294-2303
[31]
AEMPS. Enzalutamida. Ficha técnica. [Internet]. [consultado 22 Jun. 2022]. Disponible en: https://cima.aemps.es/cima/publico/lista.html
[32]
I.D. Davis, A.J. Martin, M.R. Stockler, S. Begbie, K.N. Chi, S. Chowdhury, et al.
Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer.
N Engl J Med., 381 (2019), pp. 121-131
[33]
A.J. Armstrong, R.Z. Szmulewitz, D.P. Petrylak, J. Holzbeierlein, A. Villers, A. Azad, et al.
ARCHES: A. Randomized Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer.
J Clin Oncol., 37 (2019), pp. 2974-2986
[34]
A.J. Armstrong, A.A. Azad, T. Iguchi, R.Z. Szmulewitz, D.P. Petrylak, J. Holzbeierlein, et al.
Improved Survival With Enzalutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer.
J Clin Oncol., 40 (2022), pp. 1616-1622
[35]
T. Yanagisawa, P. Rajwa, C. Thibault, G. Gandaglia, K. Mori, T. Kawada, et al.
Androgen Receptor Signaling Inhibitors in Addition to Docetaxel with Androgen Deprivation Therapy for Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review and Meta-analysis.
Eur Urol., 82 (2022), pp. 584-598
[36]
K. Fizazi, S. Foulon, J. Carles, G. Roubaud, R. McDermott, A. Fléchon, et al.
Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design.
Lancet., 399 (2022), pp. 1695-1707
[37]
E. Francini, K.P. Gray, W. Xie, G.K. Shaw, L. Valença, B. Bernard, et al.
Time of metastatic disease presentation and volume of disease are prognostic for metastatic hormone sensitive prostate cancer (mHSPC).
Prostate., 78 (2018), pp. 889-895
[38]
P. Ost, D. Reynders, K. Decaestecker, V. Fonteyne, N. Lumen, A. De Bruycker, et al.
Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence: A Prospective, Randomized Multicenter Phase II Trial.
J Clin Oncol., 36 (2018), pp. 446-453
[39]
R. Phillips, W.Y. Shi, M. Deek, N. Radwan, S.J. Lim, E.S. Antonarakis, et al.
Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer: The ORIOLE Phase 2 Randomized Clinical Trial.
JAMA Oncol., 6 (2020), pp. 650-659
[40]
Moreno AJC. Phase III Study of Stereotactic Body Radiation Therapy (SBRT) Plus Standard of Care in Castration Sensitive Oligometastatic Prostate Cancer Patients. [Internet]. clinicaltrials.gov; 2022 [consultado 20 Nov. 2022]. Disponible en: https://clinicaltrials.gov/ct2/show/NCT05209243
[41]
P.A. Tsao, M.E.V. Caram.
Factors to Guide Treatment Selection for Hormone-Sensitive Metastatic Prostate Cancer.
Cancer J Sudbury Mass., 26 (2020), pp. 76-82
[42]
A.O. Elmehrath, A.M. Afifi, M.J. Al-Husseini, A.M. Saad, N. Wilson, K.S. Shohdy, et al.
Causes of Death Among Patients With Metastatic Prostate Cancer in the US From 2000 to 2016.
JAMA Netw Open., 4 (2021), pp. e2119568
[43]
A.A. Challa, A.C. Calaway, J. Cullen, J. Garcia, N. Desai, N.L. Weintraub, et al.
Cardiovascular Toxicities of Androgen Deprivation Therapy.
Curr Treat Options Oncol., 22 (2021), pp. 47
[44]
N.L. Keating.
Cardiovascular and Metabolic Diagnoses Associated With Novel Hormonal Agents for Prostate Cancer in Nontrial Populations.
JNCI J Natl Cancer Inst., 114 (2022), pp. 1057-1058
[45]
S. Muniyan, L. Xi, K. Datta, A. Das, B.A. Teply, S.K. Batra, et al.
Cardiovascular risks and toxicity - The Achilles heel of androgen deprivation therapy in prostate cancer patients.
Biochim Biophys Acta Rev Cancer., 1874 (2020), pp. 188383
[46]
R. Iacovelli, C. Ciccarese, E. Bria, M. Romano, E. Fantinel, D. Bimbatti, et al.
The Cardiovascular Toxicity of Abiraterone and Enzalutamide in Prostate Cancer.
Clin Genitourin Cancer., 16 (2018), pp. e645-e653
[47]
R.B. Moreira, M. Debiasi, E. Francini, P.V. Nuzzo, G.D. Velasco, F.C. Maluf, et al.
Differential side effects profile in patients with mCRPC treated with abiraterone or enzalutamide: a meta-analysis of randomized controlled trials.
Oncotarget., 8 (2017), pp. 84572-84578
[48]
J. Zhu, R. Liao, C. Su, D. Liang, J. Wu, K. Qiu, et al.
Toxicity profile characteristics of novel androgen-deprivation therapy agents in patients with prostate cancer: a meta-analysis.
Expert Rev Anticancer Ther., 18 (2018), pp. 193-198
[49]
E.B. Cone, S. Reese, M. Marchese, J. Nabi, R.R. McKay, K.L. Kilbridge, et al.
Cardiovascular toxicities associated with abiraterone compared to enzalutamide–A pharmacovigilance study.
EClinicalMedicine., 36 (2021), pp. 100887
[50]
A.A. Kulkarni, N. Rubin, A. Tholkes, S. Shah, C.J. Ryan, P.L. Lutsey, et al.
Risk for stroke and myocardial infarction with abiraterone versus enzalutamide in metastatic prostate cancer patients.
ESMO Open., 6 (2021), pp. 100261
[51]
J. Hu, A.G. Aprikian, M. Vanhuyse, A. Dragomir.
Comparative Cardiovascular Safety of Novel Hormonal Agents in Metastatic Castration-Resistant Prostate Cancer Using Real-World Data.
Clin Genitourin Cancer., 20 (2022), pp. 17-24
[52]
G. George, H. Vikman, R. Gedeborg, I.F. Lissbrant, H. Garmo, J. Styrke, et al.
Risk of cardiovascular events in men on abiraterone or enzalutamide combined with GnRH agonists: nation-wide, population-based cohort study in Sweden.
Acta Oncol., 60 (2021), pp. 459-465
[53]
G. Lu-Yao, N. Nikita, S.W. Keith, G. Nightingale, K. Gandhi, S.E. Hegarty, et al.
Mortality and Hospitalization Risk Following Oral Androgen Signaling Inhibitors Among Men with Advanced Prostate Cancer by Pre-existing Cardiovascular Comorbidities.
Eur Urol., 77 (2020), pp. 158-166
[54]
E. Casado, A. Borque-Fernando, M. Caamaño, J. Graña, J. Muñoz-Rodríguez, J. Morote.
Multidisciplinary Consensus on the Prevention and Treatment of Osteoporosis and Fragility Fractures in Patients with Prostate Cancer Receiving Androgen-Deprivation Therapy.
World J Mens Health., 40 (2022), pp. 74-86
[55]
M.A. Gómez-Aparicio, F. López-Campos, L. Pelari-Mici, D. Buchser, J. Pastor, X. Maldonado, et al.
Bone health and therapeutic agents in advanced prostate cancer.
Front Biosci (Landmark Ed)., 27 (2022), pp. 34
[56]
L. Buckley, G. Guyatt, H.A. Fink, M. Cannon, J. Grossman, K.E. Hansen, et al.
2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis.
Arthritis Rheumatol., 69 (2017), pp. 1521-1537
[57]
Yasir M, Goyal A, Sonthalia S. Corticosteroid Adverse Effects [Internet]. En: StatPearls. Treasure Island (FL): StatPearls Publishing; 2022 [consultado 5 Sep. 2022]. Disponible en: http://www.ncbi.nlm.nih.gov/books/NBK531462/
[58]
A. Naranjo Hernández, P. Díaz del Campo Fontecha, M.P. Aguado Acín, L. Arboleya Rodríguez, E. Casado Burgos, S. Castañeda, et al.
Recommendations by the Spanish Society of Rheumatology on Osteoporosis.
Reumatol Clin (Engl Ed)., 15 (2019), pp. 188-210
[59]
R.C. Tripathi, S.K. Parapuram, B.J. Tripathi, Y. Zhong, K.V. Chalam.
Corticosteroids and glaucoma risk.
Drugs Aging., 15 (1999), pp. 439-450
[60]
Y. Tohi, T. Kato, H. Fukuhara, K. Kobayashi, S. Ohira, K. Ikeda, et al.
Real-world analysis of apalutamide-associated skin adverse events in Japanese patients with advanced prostate cancer: a multi-institutional study in the Chu-shikoku Japan Urological Consortium.
Int J Clin Oncol., 27 (2022), pp. 1348-1355
[61]
A. Pan, R.E. Reingold, J.L. Zhao, A. Moy, L. Kraehenbuehl, G. Dranitsaris, et al.
Dermatological Adverse Events in Prostate Cancer Patients Treated with the Androgen Receptor Inhibitor Apalutamide.
J Urol., 207 (2022), pp. 1010-1019
[62]
M.R. Smith, F. Saad, S. Chowdhury, S. Oudard, B.A. Hadaschik, J.N. Graff, et al.
Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer.
N Engl J Med., 378 (2018), pp. 1408-1418
[63]
S. Slovin, W. Clark, J. Carles, A. Krivoshik, J.W. Park, F. Wang, et al.
Seizure Rates in Enzalutamide-Treated Men With Metastatic Castration-Resistant Prostate Cancer and Risk of Seizure: The UPWARD Study.
JAMA Oncol., 4 (2018), pp. 702-706
[64]
C. Zurth, S. Sandman, D. Trummel, D. Seidel, R. Nubbemeyer, H. Gieschen.
Higher blood–brain barrier penetration of [14 C]apalutamide and [14 C]enzalutamide compared to [14 C]darolutamide in rats using whole-body autoradiography.
J Clin Oncol., 37 (2019), pp. 156
[65]
D. Hebenstreit, R. Pichler, I. Heidegger.
Drug-Drug Interactions in Prostate Cancer Treatment.
Clin Genitourin Cancer., 18 (2020), pp. e71-e82
[66]
J. Vicente-Valor, V. Escudero-Vilaplana, R. Collado-Borrell, S. Pérez-Ramírez, C. Villanueva-Bueno, Á. Narrillos-Moraza, et al.
Potential and real drug interactions in patients treated with abiraterone or enzalutamide in clinical practice.
Expert Opin Drug Metab Toxicol., 17 (2021), pp. 1467-1473
[67]
AEMPS. Ficha técnica enzalutamida. [Internet]. [consultado 14 Jun. 2020]. Disponible en: https://cima.aemps.es/cima/pdfs/ft/113846002/FT_113846002.pdf
[68]
AEMPS. Ficha técnica apalutamida [Internet]. [consultado 14 Jun. 2020]. Disponible en: https://cima.aemps.es/cima/pdfs/es/ft/1181342001/FT_1181342001.pdf
[69]
AEMPS. Ficha técnica darolutamida. [Internet]. [consultado 14 Jun. 2020]. Disponible en: https://cima.aemps.es/cima/pdfs/p/1201432001/P_1201432001.pdf
[70]
A.O. Elmehrath, A.M. Afifi, M.J. Al-Husseini, A.M. Saad, N. Wilson, K.S. Shohdy, et al.
Causes of Death Among Patients With Metastatic Prostate Cancer in the US From 2000 to 2016.
JAMA Netw Open., 4 (2021), pp. e2119568
[71]
Esperanza de vida a distintas edades. Brecha de género. España. 2010 y 2020. [Internet]. INE [consultado 22 Nov. 2022]. Disponible en: https://www.ine.es/jaxi/Datos.htm?path=/t00/mujeres_hombres/tablas_1/l0/&file=d01005.px#!tabs-tabla%20)
[72]
Life expectancy by age and sex - Products Datasets - Eurostat [Internet]. [consultado 22 Nov. 2022]. Disponible en: https://ec.europa.eu/eurostat/web/products-datasets/-/demo_mlexpec%20
asdasdasd
Opciones de artículo
Herramientas
Material suplementario